KV Pharmaceutical Co., a St. Louis-based drug company, sued Citigroup Global Markets Inc., claiming the investment banking unit compelled it to buy $73.9 million worth of illiquid auction-rate securities. The Citigroup unit misled KV, telling it that the securities were ...
Tagged with: auction Citigroup Global Markets Inc. Citigroup UBS AG illiquid auction-rate securities KV Pharmaceutical Co. U.S. Securities and Exchange Commission
Read More »